

JYOTHY LABORATORIES

FMCG

Margin under pressure

Net sales, EBITDA and Adj PAT grew 4%, -4% and 35%. Overall volumes grew 5.1% but ex-HI, the growth was higher at9.7%.Personal wash and fabric care posted decent growth of 23% and 8% (given higher share of south). Dish wash recorded muted sales growth at 4%. HI, given high share of East (wholesale channel remained affected), registered 7% sales decline. Gross margin contracted 185 bps YoY on higher RM costs, but lower other expenses (down 83 bps YoY) restricted decline in OPM (down 114 bps YoY to 13.5%).

We expect sales CAGR of 11% over FY17-19 but estimate EPS CAGR to be 37% (lower interest cost and tax rate). Valuations at 33x for FY19 appear expensive but probably pricing in a favorable offer from Henkel. Maintain HOLD with TP of Rs 360 based on 30x forward P/E.

25 MAY 2017

Quarterly Update

HOLD

Target Price: Rs 360

| CMP Potential Upside | : Rs 378 : -5% |
|-------------------------|-------------------|
| MARKET DATA | |
| No. of Shares | : 182 mn |
| Free Float | : 33% |
| Market Cap | : Rs 69 bn |
| 52-week High / Low | : Rs 427 / Rs 270 |
| Avg. Daily vol. (6mth) | : 1,46,010 shares |
| Bloomberg Code | : JYL IB Equity |
| Promoters Holding | : 67% |
| FII / DII | : 13% / 10% |
| | |

Segment performance

- Fabric care (39% of sales and 69% of EBIT) posted decent sales and EBITgrowth of 8.4% and 10.5% YoYrespectively (EBIT margin up40 bps to 22.8%). *Ujala Crisp & shine* sales grew 37%. *Henko* sales declined3% YoY. For *Ujala* portfolio, the company took price hike of 8-10% in Q1FY18
- Dish wash (26% of sales and 22% of EBIT) sales grew 4.2%, but EBIT declined 23% YoY as EBIT margin contracted 391 bps to 10.9%. *Exo* bar sales grew 5% YoY, while *Pril* liquid sales rose 2% YoY
- Household Insecticides(HI) sales remained impacted with sales and EBIT declining6.5% and 69% YoYrespectively (as EBIT margin contracted 347 bps YoY to 1.8%). The management highlighted that higher reliance on wholesale in North and East impacted coil sales (62% of HI sales, down 7.4% YoY). *Maxo*liquid vaporizer sales grew 11.5%
- Personal care sales grew strong 22.5% (on the back of *Margo* restage), with EBIT growing 46% YoY (as EBIT margin expanded 314 bps to 19.8%). The company is looking to widen Margo portfolio with extensions in naturals.

Guidance: Company is targeting volume growth of ~12% and EBITDA growth of ~15% for FY18

| Financial summary (Consolidated) | | | | | | |
|----------------------------------|--------|--------|--------|--------|--|--|
| Y/E March | FY16 | FY17P | FY18E | FY19E | | |
| Sales (Rs mn) | 16,447 | 17,356 | 19,205 | 21,340 | | |
| Adj PAT (Rs mn) | 1,140 | 1,143 | 1,638 | 2,148 | | |
| Con. EPS* (Rs) | - | - | 10.2 | 12.2 | | |
| EPS (Rs) | 6.2 | 6.1 | 8.8 | 11.5 | | |
| Change YOY (%) | 42.8 | (1.2) | 43.3 | 31.1 | | |
| P/E (x) | 60.9 | 61.7 | 43.1 | 32.8 | | |
| RoE (%) | 14.0 | 13.0 | 16.6 | 19.7 | | |
| RoCE (%) | 13.3 | 15.8 | 17.6 | 19.7 | | |
| EV/E (x) | 34.3 | 30.1 | 26.4 | 23.2 | | |
| DPS (Rs) | 4.9 | 6.0 | 5.0 | 6.0 | | |

| Key drivers | | | |
|-------------------|-------|-------|-------|
| (Rs mn) | FY17P | FY18E | FY19E |
| Revenue | 5.5% | 10.7% | 11.1% |
| Gross margin (%) | 51.3% | 50.9% | 50.6% |
| A&P spends (%) | 12.0% | 12.1% | 11.9% |
| EBITDA margin (%) | 14.4% | 14.6% | 14.9% |

Price performance



Source: *Consensus broker estimates, Company, Axis Capital



JYOTHY LABORATORIES

FMCG

Exhibit 1: Result update (Consolidated)

| (Rs mn) | Mar-17 | Mar-16 | % Chg | Dec-16 | % Chg |
|-------------------------------|--------|--------|----------|--------|----------|
| Net sales | 4,457 | 4,282 | 4.1 | 3,834 | 16.2 |
| Total revenue | 4,457 | 4,282 | 4.1 | 3,834 | 16.2 |
| Raw material cost | 2,502 | 2,324 | 7.6 | 2,089 | 19.8 |
| (% of net sales) | 56.1 | 54.3 | 185 bps | 54.5 | 164 bps |
| Staff expenditure | 417 | 391 | 6.7 | 433 | (3.7) |
| (% of net sales) | 9.3 | 9.1 | 23 bps | 11.3 | -194 bps |
| A&P spends | 281 | 275 | 2.3 | 269 | 4.5 |
| (% of net sales) | 6.3 | 6.4 | -11 bps | 7.0 | -71 bps |
| Other expenses | 656 | 665 | (1.4) | 541 | 21.1 |
| (% of net sales) | 14.7 | 15.5 | -83 bps | 14.1 | 59 bps |
| EBITDA | 601 | 627 | (4.0) | 501 | 19.9 |
| EBITDA margin (%) | 13.5 | 14.6 | -114 bps | 13.1 | 42 bps |
| Other income | 26 | 36 | (27.7) | 31 | (14.9) |
| PBIDT | 628 | 663 | (5.3) | 532 | 17.9 |
| Depreciation | 83 | 100 | (16.7) | 73 | 13.4 |
| Interest | 99 | 153 | (35.4) | 144 | (31.5) |
| РВТ | 446 | 410 | 8.7 | 315 | 41.7 |
| Ταχ | 291 | 302 | (3.5) | 108 | 170.1 |
| Adjusted PAT | 167 | 124 | 34.8 | 215 | (22.5) |
| Extra ordinary income/ (exp.) | 920 | 28 | - | 0 | - |
| Reported PAT | 1,087 | 152 | 616.9 | 215 | 405.3 |

Source: Company, Axis Capital





Exhibit 2: Volume growth trend

Source: Bloomberg, Axis Capital



25 MAY 2017 Quarterly Update
JYOTHY LABORATORIES
FMCG

Exhibit 3: 1-year forward PE



Source: Bloomberg, Axis Capital





25 MAY 2017 Quarterly Update
JYOTHY LABORATORIES
FMCG

Financial summary (Consolidated)

Profit &loss (Rs mn)

| Y/E March | FY16 | FY17P | FY18E | FY19E |
|------------------------------|---------|---------|---------|----------|
| Net sales | 16,447 | 17,356 | 19,205 | 21,340 |
| Other operating income | - | - | - | - |
| Total operating income | 16,447 | 17,356 | 19,205 | 21,340 |
| Cost of goods sold | (7,991) | (8,452) | (9,429) | (10,542) |
| Gross profit | 8,456 | 8,904 | 9,775 | 10,798 |
| Gross margin (%) | 51.4 | 51.3 | 50.9 | 50.6 |
| Total operating expenses | (6,273) | (6,400) | (6,971) | (7,629) |
| EBITDA | 2,183 | 2,504 | 2,804 | 3,169 |
| EBITDA margin (%) | 13.3 | 14.4 | 14.6 | 14.9 |
| Depreciation | (314) | (301) | (322) | (331) |
| EBIT | 1,869 | 2,203 | 2,482 | 2,838 |
| Net interest | (457) | (565) | (435) | (364) |
| Other income | 121 | 125 | 155 | 160 |
| Profit before tax | 1,533 | 1,763 | 2,202 | 2,634 |
| Total taxation | (393) | (660) | (604) | (527) |
| Tax rate (%) | 25.6 | 37.4 | 27.4 | 20.0 |
| Profit after tax | 1,140 | 1,103 | 1,598 | 2,108 |
| Minorities | - | 40 | 40 | 40 |
| Profit/ Loss associate co(s) | - | - | - | - |
| Adjusted net profit | 1,140 | 1,143 | 1,638 | 2,148 |
| Adj. PAT margin (%) | 6.9 | 6.6 | 8.5 | 10.1 |
| Net non-recurring items | 440 | - | - | - |
| Reported net profit | 1,580 | 1,143 | 1,638 | 2,148 |

Balance sheet (Rs mn)

| Y/E March | FY16 | FY17P | FY18E | FY19E |
|-------------------------------|---------|---------|---------|---------|
| | | | | |
| Paid-up capital | 181 | 182 | 182 | 182 |
| Reserves & surplus | 8,280 | 8,997 | 10,333 | 11,134 |
| Net worth | 8,461 | 9,179 | 10,514 | 11,315 |
| Borrowing | 6,116 | 5,179 | 4,490 | 3,590 |
| Other non-current liabilities | 253 | 253 | 253 | 253 |
| Total liabilities | 14,848 | 14,677 | 15,284 | 15,145 |
| Gross fixed assets | 13,104 | 13,697 | 14,097 | 14,497 |
| Less: Depreciation | (2,426) | (2,726) | (3,048) | (3,379) |
| Net fixed assets | 10,678 | 10,970 | 11,049 | 11,118 |
| Add: Capital WIP | 79 | 88 | 88 | 88 |
| Total fixed assets | 10,757 | 11,058 | 11,136 | 11,205 |
| Total Investment | 835 | - | - | - |
| Inventory | 1,827 | 1,964 | 2,105 | 2,222 |
| Debtors | 941 | 1,171 | 894 | 994 |
| Cash & bank | 612 | 358 | 1,074 | 703 |
| Loans & advances | 2,626 | 2,757 | 2,895 | 3,040 |
| Current liabilities | 2,825 | 2,706 | 2,895 | 3,094 |
| Net current assets | 3,256 | 3,619 | 4,148 | 3,940 |
| Other non-current assets | - | - | - | - |
| Total assets | 14,848 | 14,677 | 15,284 | 15,145 |

Source: Company, Axis Capital

Cash flow (Rs mn)

| Y/E March | FY16 | FY17P | FY18E | FY19E |
|-----------------------------|---------|----------------|---------|---------|
| Profit before tax | 1,533 | 1,763 | 2,202 | 2,634 |
| Depreciation & Amortisation | 314 | 301 | 322 | 331 |
| Chg in working capital | 32 | (61 <i>7</i>) | 187 | (163) |
| Cash flow from operations | 1,915 | 2,147 | 3,207 | 2,479 |
| Capital expenditure | (274) | (601) | (400) | (400) |
| Cash flow from investing | (456) | 358 | (245) | (240) |
| Equity raised/ (repaid) | - | 1 | - | - |
| Debt raised/ (repaid) | (1,168) | (938) | (689) | (900) |
| Dividend paid | (1,743) | (1,346) | (1,122) | (1,346) |
| Cash flow from financing | (3,024) | (2,759) | (2,246) | (2,610) |
| Net chg in cash | (1,566) | (254) | 716 | (371) |

| Key ratios | | | | |
|----------------------------|------|-------|-------|-------|
| Y/E March | FY16 | FY17P | FY18E | FY19E |
| OPERATIONAL | | | | |
| FDEPS (Rs) | 6.2 | 6.1 | 8.8 | 11.5 |
| CEPS (Rs) | 10.3 | 7.7 | 10.5 | 13.3 |
| DPS (Rs) | 4.9 | 6.0 | 5.0 | 6.0 |
| Dividend payout ratio (%) | 57.3 | 97.9 | 56.9 | 52.1 |
| GROWTH | | | | |
| Net sales (%) | 9.3 | 5.5 | 10.7 | 11.1 |
| EBITDA (%) | 42.2 | 14.7 | 12.0 | 13.0 |
| Adj net profit (%) | 43.8 | 0.3 | 43.3 | 31.1 |
| FDEPS (%) | 42.8 | (1.2) | 43.3 | 31.1 |
| PERFORMANCE | | | | |
| RoE (%) | 14.0 | 13.0 | 16.6 | 19.7 |
| RoCE (%) | 13.3 | 15.8 | 17.6 | 19.7 |
| EFFICIENCY | | | | |
| Asset turnover (x) | 1.2 | 1.2 | 1.4 | 1.5 |
| Sales/ total assets (x) | 0.9 | 1.0 | 1.1 | 1.2 |
| Working capital/ sales (x) | 0.1 | 0.2 | 0.2 | 0.1 |
| Receivable days | 20.9 | 24.6 | 17.0 | 17.0 |
| Inventory days | 46.7 | 48.3 | 46.8 | 44.6 |
| Payable days | 41.2 | 36.6 | 37.4 | 37.7 |
| FINANCIAL STABILITY | | | | |
| Total debt/ equity (x) | 0.8 | 0.6 | 0.5 | 0.3 |
| Net debt/ equity (x) | 0.7 | 0.5 | 0.3 | 0.3 |
| Current ratio (x) | 2.2 | 2.3 | 2.4 | 2.3 |
| Interest cover (x) | 4.1 | 3.9 | 5.7 | 7.8 |
| VALUATION | | | | |
| PE (x) | 60.9 | 61.7 | 43.1 | 32.8 |
| EV/ EBITDA (x) | 34.3 | 30.1 | 26.4 | 23.2 |
| EV/ Net sales (x) | 4.6 | 4.3 | 3.8 | 3.4 |
| PB (x) | 8.2 | 7.7 | 6.7 | 6.2 |
| Dividend yield (%) | 1.3 | 1.6 | 1.3 | 1.6 |
| Free cash flow yield (%) | 2.4 | 2.2 | 4.0 | 2.9 |



Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

- 1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
- 2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
- 3. ASL has no material adverse disciplinary history as on the date of publication of this report.
- 4. I/We, authors (Research team) and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associates do not have any material conflict of interest. I/we have not served as director, officer or employee in the subject company.

Research Team

| Sr | . No | Name | Designation | E-mail |
|----|------|--------------|------------------|--------------------------------|
| | 1 | Bunty Chawla | Research Analyst | bunty.chawla@axissecurities.in |
| | 2 | Kiran Gawle | Associate | kiran.gawle@axissecurities.in |

5. ASL or its associates has not received any compensation from the subject company in the past twelve months. ASL or its Research Analysts has not been engaged in market making activity for the subject company.

6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:

- i. Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or;
- ii. Managed or co-managed public offering of the securities from the subject company of this research report and / or;
- iii. Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report;

ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report

Term& Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.





| DEFINITION OF RATINGS | | |
|---|----------------|--|
| Ratings Expected absolute returns over 12-18 months | | |
| BUY | More than 10% | |
| HOLD Between 10% and -10% | | |
| SELL | Less than -10% | |

Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advise necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, Corporate office: Unit No. 2, Phoenix Market City, 15, LBS Road, Near Kamani Junction, Kurla (west), Mumbai-400070, Tel No. – 18002100808/022-61480808, Regd. off.- Axis House, 8th Floor, Wadia International Centre, PandurangBudhkarMarg, Worli, Mumbai – 400 025. Compliance Officer: AnandShaha, Email: compliance.officer@axisdirect.in, Tel No: 022-42671582.

